Jack Brzezinski

Associate Professor

University of Washington
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jack Brzezinski is an Associate Professor at the University of Washington, USA. His research primarily focuses on cancer predisposition syndromes, particularly in pediatric populations, and includes recent work on retinoblastoma, PTEN hamartoma tumor syndrome, and Wilms tumor predisposition. He contributes significant insights into surveillance recommendations and treatment strategies for various tumor syndromes in children.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Introduction The purpose of this study is to examine the outcomes in children with anaplastic bilateral Wilms tumor (BWT) from study AREN0534 in order to define potential prognostic factors and areas to target in future clinical trials. Methods Demographic and clinical data from AREN0534 study patients with anaplasia (focal anaplasia [FA], or diffuse anaplasia [DA]) were compared. Event‐free survival (EFS) and overall survival (OS) were reported using Kaplan–Meier estimation with 95% confidence bands, and differences in outcomes between FA and DA compared using log‐rank tests. The impact of margin status was analyzed. Results Twenty‐seven children who enrolled on AREN0534 had evidence of anaplasia (17 DA, 10 FA) in at least one kidney and were included in this analysis. Twenty‐six (96%) had BWT. Nineteen percent had anaplastic histology in both kidneys (four of 17 DA, and one of 10 FA). Forty‐six percent with BWT had bilateral nephron‐sparing surgery (NSS); one child who went off protocol therapy, eventually required bilateral completion nephrectomies. Median follow‐up for EFS and OS was 8.6 and 8.7 years from enrollment. Four‐ and 8‐year EFS was 53% [95% confidence interval (CI): 34%–83%] for DA; 4‐year EFS was 80% [95% CI: 59%–100%], and 8‐year EFS 70% [95% CI: 47%–100%] for FA. Three out of 10 children with FA and eight out of 17 children with DA had events. EFS did not differ statistically by margin status ( p = .79; HR = 0.88). Among the six children who died (five DA, one FA), all experienced prior relapse or progression within 18 months. Conclusion Events in children with DA/FA in the setting of BWT occurred early. Caution should be taken about interpreting the impact of margin status outcomes in the context of contemporary multimodal therapy. Future targeted investigations in children with BWT and DA/FA are needed.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (10)

Daniel Benedetti

Vanderbilt University Medical Center

UNITED STATES
View details

Conrad Fernandez

Professor Division of Pediatric Hematology Oncology

Dalhousie University

CANADA
View details

Daniela Perotti

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Kara Maxwell

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Alessandro Gasparetto

Assistant professor

Hospital for Sick Children

CANADA
View details

Brenda Gallie

Head Retinoblastoma Program

Hospital for Sick Children

CANADA
View details

Sarah Scollon

Assistant Professsor/Genetic Counselor

Baylor College of Medicine

UNITED STATES
View details

Peter F. Ehrlich

-

UNITED STATES
View details

Jonathan Finlay

Emeritus Professor

The Ohio State University College of Medicine

UNITED STATES
View details

Jennifer Aldrink

Professor of Clinical Surgery and Pediatrics

Nationwide Children's Hospital

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.